Back to news

Vistagen Therapeutics Surges on Positive Extension Data for Fasedienol

Investivoq PriceTracker

Vistagen Therapeutics (VTGN) is up 68.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp move appears tied to newly disclosed positive extension-study data for fasedienol, the company’s nasal spray candidate for social anxiety disorder. Investors seem to be treating the update as a sign that the program may still have regulatory and commercial potential, even after the randomized portion of PALISADE-4 failed to meet its main endpoint earlier this year.

Details:

  • Vistagen disclosed in a September 22 Form 8-K and matching company release that it saw preliminary positive data from the open-label extension portion of its PALISADE-4 Phase 3 study.
  • The company said fasedienol was well tolerated in 322 patients using the treatment as needed for up to 12 months, with no new drug-related safety findings and no discontinuations attributed to the drug.
  • Exploratory measures showed improvement over time on both clinician-rated and patient-reported social anxiety scales, including a 31.4-point mean improvement on LSAS by month four and a 14.9-point mean improvement on SPIN by month four.
  • Management also said it plans to meet with the FDA this quarter to discuss a proposed new registrational Phase 3 trial, which likely added to optimism around a possible path forward.

    • Sources:

    SEC, Vistagen Therapeutics

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    Investivoq Alerts
    Receive VTGN Data Alerts
    Get market-moving data, filings, and signals for VTGN in real time.
    Sign Up

    $VTGN Hedge Fund Activity

    We have seen 23 institutional investors add shares of $VTGN stock to their portfolio, and 40 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • ORBIMED ADVISORS LLC removed 3,060,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $691,560
    • COMMODORE CAPITAL LP added 2,788,620 shares (+inf%) to their portfolio in Q2 2026, for an estimated $630,228
    • TCG CROSSOVER MANAGEMENT, LLC removed 2,676,580 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $604,907
    • RENAISSANCE TECHNOLOGIES LLC added 439,200 shares (+150.8%) to their portfolio in Q2 2026, for an estimated $99,259
    • MILLENNIUM MANAGEMENT LLC removed 430,404 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $97,271
    • ADAR1 CAPITAL MANAGEMENT, LLC removed 400,000 shares (-53.3%) from their portfolio in Q2 2026, for an estimated $90,400
    • TWO SIGMA INVESTMENTS, LP added 378,373 shares (+80.6%) to their portfolio in Q2 2026, for an estimated $85,512

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.